The SWI/SNF chromatin remodeling factor DPF3 regulates metastasis of ccRCC by modulating TGF-β signaling

Huanhuan Cui, Hongyang Yi, Hongyu Bao, Ying Tan, Chi Tian, Xinyao Shi, Diwen Gan, Bin Zhang, Weizheng Liang, Rui Chen, Qionghua Zhu, Liang Fang, Xin Gao, Hongda Huang, Ruijun Tian, Silke Sperling, Yuhui Hu, Wei ChenNature Communications 2022 · DOI

Abstract

DPF3, a component of the SWI/SNF chromatin remodeling complex, has been associated with clear cell renal cell carcinoma (ccRCC) in a genome-wide association study. However, the functional role of DPF3 in ccRCC development and progression remains unknown. In this study, we demonstrate that DPF3a, the short isoform of DPF3, promotes kidney cancer cell migration both in vitro and in vivo, consistent with the clinical observation that DPF3a is significantly upregulated in ccRCC patients with metastases. Mechanistically, DPF3a specifically interacts with SNIP1, via which it forms a complex with SMAD4 and p300 histone acetyltransferase (HAT), the major transcriptional regulators of TGF-β signaling pathway. Moreover, the binding of DPF3a releases the repressive effect of SNIP1 on p300 HAT activity, leading to the increase in local histone acetylation and the activation of cell movement related genes. Overall, our findings reveal a metastasis-promoting function of DPF3, and further establish the link between SWI/SNF components and ccRCC.

Introduction

Clear cell renal cell carcinoma (ccRCC) is the most common and aggressive form of kidney cancer, notorious for its metastatic potential and resistance to standard therapies. While genomic studies have identified mutations in the SWI/SNF chromatin remodeling complex—specifically PBRM1—as hallmark drivers of the disease, the role of other complex components like DPF3 has remained poorly understood. Previous genome-wide association studies (GWAS) flagged DPF3 as a significant risk locus, but the molecular mechanisms by which it contributes to cancer progression were previously undefined. This study aims to bridge that gap by characterizing the functional role of DPF3 isoforms in ccRCC metastasis.

Methods

The research team employed a multi-disciplinary approach to dissect DPF3 function:

  • Genomic and Epigenomic Profiling: RNA-seq was used to identify differentially expressed genes, while ATAC-seq and ChIP-seq mapped chromatin accessibility and protein-DNA binding sites, respectively.
  • Proteomics: Immunoprecipitation-Mass Spectrometry (IP-MS) identified the DPF3a interactome.
  • Functional Assays: In vitro migration and invasion assays were complemented by in vivo mouse models of splenic injection to track liver metastasis.
  • Biochemical Validation: In vitro histone acetyltransferase (HAT) assays measured the impact of DPF3a on p300 enzymatic activity.
  • Clinical Data: The study utilized the TCGA-KIRC dataset (534 ccRCC and 72 normal samples) for clinical correlations.

Key Insights: The DPF3a-SNIP1-p300 Axis

A central finding of the study is that the functional impact of DPF3 is isoform-specific. DPF3 exists in two forms: DPF3a and DPF3b. Only the shorter isoform, DPF3a, promotes metastasis due to its unique C-terminal domain. The study also linked DPF3a upregulation to VHL mutations—the primary genetic driver of ccRCC—suggesting that DPF3a is a key downstream effector of the oncogenic signaling initiated by VHL loss.

Mechanistically, DPF3a acts as an epigenetic "brake release." In normal cells, the protein SNIP1 inhibits p300 histone acetyltransferase activity, keeping pro-metastatic genes silenced. In ccRCC, upregulated DPF3a binds to SNIP1, displacing it from p300. This allows p300 to acetylate histones at the promoters of TGF-β target genes, such as SNAI1 and MMP2, triggering the epithelial-mesenchymal transition (EMT) and enabling cancer cells to migrate.

Key Results: Clinical Correlation and Metastatic Potential

Clinical analysis confirms that DPF3 expression is significantly upregulated in ccRCC compared to normal tissues (p=0.0007). Exon-level expression data further reveals that this increase is driven by the DPF3a-specific isoform, with exon E9 showing marked elevation in tumor samples.

DPF3 isoform splicing and expression analysis in ccRCC.

Functional experiments demonstrated that overexpressing DPF3a dramatically increases liver metastasis in mouse models. Conversely, knocking down DPF3 significantly reduces the invasive capacity of kidney cancer cells. Interestingly, ATAC-seq revealed that DPF3a does not significantly alter chromatin "openness" but rather modulates the chemical landscape (acetylation) of histones, functioning as a transcriptional co-activator to drive the expression of invasive gene signatures.

Conclusion

This study establishes DPF3a as a critical driver of metastasis in clear cell renal cell carcinoma. By hijacking the TGF-β signaling pathway through a novel protein interaction with SNIP1 and p300, DPF3a facilitates the transition of localized tumors into invasive disease. These findings provide a functional explanation for GWAS-identified risk at the DPF3 locus and suggest that targeting the DPF3a-SNIP1 interaction could offer a new therapeutic strategy for treating aggressive kidney cancer.

Summary updated

Abstract

DPF3, a component of the SWI/SNF chromatin remodeling complex, has been associated with clear cell renal cell carcinoma (ccRCC) in a genome-wide association study. However, the functional role of DPF3 in ccRCC development and progression remains unknown. In this study, we demonstrate that DPF3a, the short isoform of DPF3, promotes kidney cancer cell migration both in vitro and in vivo, consistent with the clinical observation that DPF3a is significantly upregulated in ccRCC patients with metastases. Mechanistically, DPF3a specifically interacts with SNIP1, via which it forms a complex with SMAD4 and p300 histone acetyltransferase (HAT), the major transcriptional regulators of TGF-β signaling pathway. Moreover, the binding of DPF3a releases the repressive effect of SNIP1 on p300 HAT activity, leading to the increase in local histone acetylation and the activation of cell movement related genes. Overall, our findings reveal a metastasis-promoting function of DPF3, and further establish the link between SWI/SNF components and ccRCC.
BibTeX
@inproceedings{cui2022swi,
  author = {Huanhuan Cui and Hongyang Yi and Hongyu Bao and Ying Tan and Chi Tian and Xinyao Shi and Diwen Gan and Bin Zhang and Weizheng Liang and Rui Chen and Qionghua Zhu and Liang Fang and Xin Gao and Hongda Huang and Ruijun Tian and Silke Sperling and Yuhui Hu and Wei Chen},
  title = {{The SWI/SNF chromatin remodeling factor DPF3 regulates metastasis of ccRCC by modulating TGF-β signaling}},
  booktitle = {Nature Communications},
  year = {2022},
  doi = {10.1038/s41467-022-32472-0},
}
Figure